Baricitinib and Weed
Edited by Hugh Soames
Advertising: We may earn a commission if you buy anything via our advertising or external links
Baricitinib and Weed
Most people who consume marijuana do so for its mood-altering and relaxing abilities. Weed gives people a high and allows them to relax. However, heavy consumption of weed can cause unwanted results. It can increase the anxiety and depression a person experiences, and it can interact with certain other drugs including Baricitinib. It is important to remember that interactions do occur with all types of drugs, to a great or lesser extent and this article details the interactions of mixing Baricitinib and Weed.
Mixing Baricitinib and Weed
Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Baricitinib is approved for medical use in the European Union and in the United States.
An important side effect of JAK inhibitors is serious bacterial, mycobacterial, fungal and viral infections.
In February 2017, baricitinib was approved for use in the European Union as a second-line therapy for moderate to severe active rheumatoid arthritis in adults, either alone or in combination with methotrexate.
In May 2018, the US Food and Drug Administration (FDA) approved baricitinib for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
In May 2022, the FDA approved baricitinib for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). baricitinib is the first immunomodulatory treatment for COVID-19 to receive FDA approval.
In the United States, baricitinib is authorized under an emergency use authorization (EUA) for the treatment of COVID-19 in hospitalized people aged 2 to less than 18 years of age who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
In June 2022, the FDA authorized baricitinib for the treatment of severe alopecia areata.
During pregnancy, the use of baricitinib is contraindicated.
In studies, upper respiratory tract infections and high blood cholesterol levels (hypercholesterolemia) occurred in more than 10% of patients. Less common side effects included other infections such as herpes zoster, herpes simplex, urinary tract infections, and gastroenteritis.
Being metabolized only to a small extent, the substance has a low potential for interactions. In studies, inhibitors of the liver enzymes CYP3A4, CYP2C19, and CYP2C9, as well as the CYP3A4 inducer rifampicin, had no relevant influence on baricitinib concentrations in the bloodstream. While baricitinib blocks a number of transporter proteins in vitro, clinically relevant interactions via this mechanism are considered very unlikely, except perhaps for the cation transporter SLC22A1 (OCT1).
An additive effect with other immunosuppressants cannot be excluded.
Baricitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits Janus kinase 1 with a half maximal inhibitory concentration (IC50) of 5.9 nM and Janus kinase 2 with an IC50 of 5.7 nM. Tyrosine kinase 2, which belongs to the same enzyme family, is affected less (IC50 = 53 nM), and Janus kinase 3 far less (IC50 > 400 nM). Via a signal transduction pathway involving STAT proteins, this ultimately modulates gene expression in immunological cells.
Other JAK inhibitors include tofacitinib, which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; fedratinib, and ruxolitinib.
The substance is quickly absorbed from the gut with an absolute bioavailability of 79%. It reaches highest blood plasma levels after about an hour; in different individuals the time to reach this level ranges from 0.5 to 3 hours. Food intake has no relevant influence on the drug’s pharmacokinetics. 50% of the circulating baricitinib are bound to blood plasma proteins.
Less than 10% of the substance is metabolized to four different oxidation products by CYP3A4; the rest is left unchanged. Elimination half-life is 12.5 hours on average. About 75% is eliminated via the urine, and 20% via the faeces.
Baricitinib was discovered by Incyte and licensed to Eli Lilly.
In January 2016, Eli Lilly submitted a new drug application to the US Food and Drug Administration (FDA) for the approval of baricitinib to treat moderately-to-severely active rheumatoid arthritis.
In December 2016, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of baricitinib as a therapy for rheumatoid arthritis. European Union approval was granted in February 2017.
Despite widespread expectations that the FDA would approve baricitinib for rheumatoid arthritis, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety.
In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis.
In March 2020, the US FDA granted breakthrough therapy designation to baricitinib for the treatment of alopecia areata and granted approval in June 2022.
The efficacy and safety of baricitinib in alopecia areata was studied in two randomized, double-blind, placebo-controlled trials (Trial AA-1 and Trial AA-2) with participants who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool for more than six months. Participants in these trials received either a placebo, 2 milligrams of Olumiant, or 4 milligrams of Olumiant every day. The primary measurement of efficacy for both trials was the proportion of patients who achieved at least 80% scalp hair coverage at week 36.
As of August 2016, 31 clinical trials had been registered for baricitinib of which 24 had completed, and 4 of 6 phase 3 trials had completed.[needs update]
As of March 2022, a phase III clinical trial showed hair regrowth for those with alopecia areata.
In April 2020, Lilly announced they were investigating the use of baricitinib for treating people with COVID-19. The drug’s anti-inflammatory activity was expected to act on the inflammatory cascade associated with COVID-19.
In April and June 2020, the first two studies of baricitinib prescribed for hospitalized patients with COVID-19 were published online. Then in November 2020, published research showed baricitinib was beneficial in treating people with COVID-19. According to the paper “mechanistic actions of a Janus kinase-1/2 inhibitor targeting viral entry, replication and the cytokine storm, and is associated with beneficial outcomes including in severely ill elderly people”.
In a clinical trial of hospitalized people with COVID-19, baricitinib, in combination with remdesivir, was shown to reduce time to recovery within 29 days after initiating treatment compared to participants who received a placebo with remdesivir.
The data supporting the US Food and Drug Administration (FDA) emergency use authorization (EUA) for baricitinib combined with remdesivir was based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the US National Institute of Allergy and Infectious Diseases (NIAID). This clinical trial evaluated whether baricitinib impacted how long it took for subjects who were also taking remdesivir to recover from COVID-19. The trial followed participants for 29 days and included 1,033 participants with moderate or severe COVID-19; 515 participants received baricitinib plus remdesivir, and 518 participants received placebo plus remdesivir. Recovery was defined as either being discharged from the hospital or being hospitalized but not requiring supplemental oxygen and no longer requiring ongoing medical care. The median time to recovery from COVID-19 was seven days for baricitinib plus remdesivir and eight days for placebo plus remdesivir. The odds of a patient’s condition progressing to death or being ventilated at day 29 was 31% lower in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. The odds of clinical improvement at day 15 was 30% higher in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. For all of these endpoints, the effects were statistically significant. The EUA was issued to Eli Lilly and Company.
In November 2020, the World Health Organization (WHO) updated its guideline on therapeutics for COVID-19 to include a conditional recommendation against the use of remdesivir, triggered by results from the WHO Solidarity trial.
In November 2020, the FDA issued an emergency use authorization (EUA) for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized people aged two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Then in September 2021, the largest randomized, placebo-controlled trial of hospitalized patients with COVID-19 to date, COV-BARRIER, was published. This trial randomized 1525 participants to either baricitinib or placebo. Nearly 80% of participants were receiving systemic corticosteroids at enrollment. There was an absolute risk reduction of 2.7 percent in the primary endpoint of progression to high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation, or death by day 28. The 38.2% statistically significant reduction in all-cause 28-day mortality for participants receiving baricitinib compared to placebo was the largest mortality reduction to date and maintained at 60 days. This translates into one additional death prevented for every 20 patients treated with baricitinib. The frequencies of serious adverse events were lower for participants receiving baricitinib compared to those receiving placebo.[citation needed]
As of April 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is evaluating the use of baricitinib to include treatment of COVID-19 in hospitalized patients from ten years of age who require supplemental oxygen.
In July 2021, the FDA revised the EUA for baricitinib now authorizing it alone for the treatment of COVID-19 in hospitalized people aged two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Under the revised EUA, baricitinib is not required to be administered with remdesivir.
As of January 2022, the World Health Organization strongly recommended baricitinib for patients with severe or critical COVID-19. Thereafter in February 2022, an exploratory randomized, placebo-controlled trial of patients receiving invasive mechanical ventilation or extracorporeal membrane oxygenation were randomly to baricitinib or placebo. There was a 46% statistically significant relative reduction in all-cause mortality for participants receiving baricitinib compared to those receiving placebo at 28 days which was sustained at 60 days.
Then in May 2022, the FDA approved use of baricitinib for the treatment of adult patients hospitalized with COVID-19 who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation with a recommended dose of 4 mg once daily for 14 days or until hospital discharge, whichever happens first.
On 3 March 2022, the RECOVERY trial reported that the use of baricitinib cut the risk of death by about a fifth in about 12,000 participants.
Research has found that anxiety is one of the leading symptoms created by marijuana in users, and that there is a correlation between Baricitinib and Weed and an increase in anxiety.
Anyone mixing Baricitinib and weed is likely to experience side effects. This happens with all medications whether weed or Baricitinib is mixed with them. Side effects can be harmful when mixing Baricitinib and weed. Doctors are likely to refuse a patient a Baricitinib prescription if the individual is a weed smoker or user. Of course, this could be due to the lack of studies and research completed on the mixing of Baricitinib and Weed.
Heavy, long-term weed use is harmful for people. It alters the brain’s functions and structure, and all pharmaceuticals and drugs including Baricitinib are designed to have an impact on the brain. There is a misplaced belief that pharmaceuticals and medication work by treating only the parts of the body affected yet this is obviously not the case in terms of Baricitinib. For example, simple painkiller medication does not heal the injury, it simply interrupts the brains functions to receive the pain cause by the injury. To say then that two drugs, Baricitinib and Weed, dol not interact is wrong. There will always be an interaction between Baricitinib and Weed in the brain11.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678684/.
One of the milder side effects of mixing Baricitinib and Weed is Scromiting. This condition, reportedly caused by mixing Baricitinib and Weed, describes a marijuana-induced condition where the user experiences episodes of violent vomiting, which are often so severe and painful that they cause the person to scream. The medical term for Scromiting by mixing Baricitinib and Weed is cannabinoid hyperemesis syndrome, or CHS. For these reasons, some people choose to quit smoking weed.
It was first included in scientific reports in 2004. Since then, researchers have determined that Scromiting is the result of ongoing, long-term use of marijuana—particularly when the drug contains high levels of THC, marijuana’s main psychoactive ingredient. Some experts believe that the receptors in the gut become overstimulated by THC, thus causing the repeated cycles of vomiting.
In the long run, a person can become even more depressed. There is a belief that marijuana is all-natural and not harmful to a person’s health. This is not true and Baricitinib and weed can cause health issues the more a person consumes it.
How does Weed effect the potency of Baricitinib?
The way in which the body absorbs and process Baricitinib may be affected by weed. Therefore, the potency of the Baricitinib may be less effective. Marijuana inhibits the metabolization of Baricitinib. Not having the right potency of Baricitinib means a person may either have a delay in the relief of their underlying symptoms.
A person seeking Baricitinib medication that uses weed should speak to their doctor. It is important the doctor knows about a patient’s weed use, so they can prescribe the right Baricitinib medication and strength. Or depending on level of interactions they may opt to prescribe a totally different medication. It is important for the doctor to know about their patient’s marijuana use. Weed is being legalized around the US, so doctors should be open to speaking about a patient’s use of it.
Sideffects of Baricitinib and Weed
Many individuals may not realize that there are side effects and consequences to mixing Baricitinib and Weed such as:
- Dizziness
- Sluggishness
- Drowsiness
- Shortness of breath
- Itching
- Hives
- Palpitations
- Respiratory Depression
- Cardiac Arrest
- Coma
- Seizures
- Death
Interestingly, it is impossible to tell what effect mixing this substance with Weed will have on an individual due to their own unique genetic make up and tolerance. It is never advisable to mix Baricitinib and Weed due to the chances of mild, moderate and severe side effects. If you are having an adverse reaction from mixing Baricitinib and Weed it’s imperative that you head to your local emergency room. Even mixing a small amount of Baricitinib and Weed is not recommended.
Taking Baricitinib and Weed together
People who take Baricitinib and Weed together will experience the effects of both substances. Technically, the specific effects and reactions that occur due to frequent use of Baricitinib and weed depend on whether you consume more weed in relation to Baricitinib or more Baricitinib in relation to weed.
The use of significantly more weed and Baricitinib will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.
People who take both weed and Baricitinib may experience effects such as:
- reduced motor reflexes from Baricitinib and Weed
- dizziness from Weed and Baricitinib
- nausea and vomiting due to Baricitinib and Weed
Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Baricitinib leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.
Mixing weed and Baricitinib
The primary effect of weed is influenced by an increase in the concentration of the inhibitory neurotransmitter GABA, which is found in the spinal cord and brain stem, and by a reduction in its effect on neuronal transmitters. When weed is combined with Baricitinib this primary effect is exaggerated, increasing the strain on the body with unpredictable results.
Weed and Baricitinib affects dopamine levels in the brain, causing the body both mental and physical distress. Larger amounts of Baricitinib and weed have a greater adverse effect yet leading medical recommendation is that smaller does of Baricitinib can be just as harmful and there is no way of knowing exactly how Baricitinib and weed is going to affect an individual before they take it.
Taking Baricitinib and weed together
People who take Baricitinib and weed together will experience the effects of both substances. The use of significantly more Baricitinib with weed will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.
People who take both weed and Baricitinib may experience effects such as:
- reduced motor reflexes from Baricitinib and weed
- dizziness from weed and Baricitinib
- nausea and vomiting of the Baricitinib
Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Baricitinib leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.
Weed Vs Baricitinib
Taking Baricitinib in sufficient quantities increases the risk of a heart failure. Additionally, people under the influence of Baricitinib and weed may have difficulty forming new memories. With weed vs Baricitinib in an individual’s system they become confused and do not understand their environment. Due to the synergistic properties of Baricitinib when mixed with weed it can lead to confusion, anxiety, depression and other mental disorders. Chronic use of Baricitinib and weed can lead to permanent changes in the brain22.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741114/.
Baricitinib Vs Weed
Studies investigating the effects of drugs such as Baricitinib and weed have shown that the potential for parasomnia (performing tasks in sleep) is dramatically increased when Baricitinib and weed are combined. Severe and dangerous side effects can occur when medications are mixed in the system, and sleep disorders are a common side effect of taking weed and Baricitinib together.
When a small to medium amount of weed is combined with Baricitinib, sleep disorders such as sleep apnea can occur. According to the latest data from the US Centers for Disease Control and Prevention (CDC) most ER visits and hospitalizations caused by too much weed were associated with other substances such as Baricitinib.
How long after taking Baricitinib can I smoke weed or take edibles?
To avoid any residual toxicity it is advisable to wait until the Baricitinib has totally cleared your system before taking weed, even in small quantities.
Overdose on Baricitinib and weed
In the case of Overdose on Baricitinib or if you are worried after mixing Baricitinib and weed, call a first responder or proceed to the nearest Emergency Room immediately.
If you are worried about someone who has taken too much Baricitinib or mixed weed with Baricitinib then call a first responder or take them to get immediate medical help. The best place for you or someone you care about in the case of a medical emergency is under medical supervision. Be sure to tell the medical team that there is a mix of Baricitinib and weed in their system.
Excessive Weed intake and result in scromiting, chs, and anxiety disorder. It is advisable to quit vaping weed if you are feeling these symptoms.
Mixing Baricitinib and weed and antidepressants
Weed users feeling depressed and anxious may be prescribed antidepressant medication. There are some antidepressant users who also use Baricitinib and weed. These individuals may not realize that there are side effects and consequences to consuming both Baricitinib, marijuana and a range of antidepressants.
Studies on weed, Baricitinib and antidepressants is almost nil. The reason for so little information on the side effects of the two is mostly down to marijuana being illegal in most places – although a number of states in the United States have legalized the drug.
Self-medicating with Weed and Baricitinib
A lot of people suffer from depression caused by weed and Baricitinib. How many? According to Anxiety and Depression Association of America (ADAA), in any given year, it is estimated that nearly 16 million adults experience depression. Unfortunately, that number is likely to be wrong due to under reporting. Many people do not report suffering from depression because they do not want to be looked at as suffering from a mental illness. The stigmas around mental health continue and people do not want to be labeled as depressed.
Potential side effects from mixing Baricitinib and weed
Quitting weed to take Baricitinib
Medical professionals say an individual prescribed or taking Baricitinib should not stop using weed cold turkey. Withdrawal symptoms can be significant. Heavy pot users should especially avoid going cold turkey. The side effects of withdrawal from weed include anxiety, irritability, loss of sleep, change of appetite, and depression by quitting weed cold turkey and starting to take Baricitinib.
A person beginning to use Baricitinib should cut back on weed slowly. While reducing the amount of weed use, combine it with mindfulness techniques and/or yoga. Experts stress that non-medication can greatly improve a person’s mood.
Weed and Baricitinib can affect a person in various ways. Different types of marijuana produce different side effects. Side effects of weed and Baricitinib may include:
- loss of motor skills
- poor or lack of coordination
- lowered blood pressure
- short-term memory loss
- increased heart rate
- increased blood pressure
- anxiety
- paranoia
- increased energy
- increased motivation
Mixing Baricitinib and weed can also produce hallucinations in users. This makes marijuana a hallucinogenic for some users. Weed creates different side effects in different people, making it a very potent drug. Now, mixing Baricitinib or other mental health drugs with weed can cause even more unwanted side effects.
Mixing drugs and weed conclusion
Long-term weed use can make depression and anxiety worse. In addition, using marijuana can prevent Baricitinib from working to their full potential33.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678684/. Weed consumption should be reduced gradually to get the most out of prescription medication. Marijuana is a drug and it is harmful to individual’s long-term health. Weed has many side effects and the consequences are different to each person who uses it, especially when mixed with Baricitinib.
If you take Baricitinib, and also drink Alcohol or MDMA, you can research the effects of Baricitinib and Alcohol , Baricitinib and Cocaine as well as Baricitinib and MDMA here.
To find the effects of other drugs and weed refer to our Weed and Other Drugs Index A to L or our Weed and Other Drugs Index M-Z.
Or you could find what you are looking for in our Alcohol and Interactions with Other Drugs index A to L or Alcohol and Interactions with Other Drugs index M to Z , Cocaine and Interactions with Other Drugs index A to L or Cocaine and Interactions with Other Drugs index M to Z or our MDMA and Interactions with Other Drugs Index A to L or MDMA and Interactions with Other Drugs Index M to Z.
Baricitinib and Weed
Counselling for Weed Addiction; Low Cost - Qualified Therapists - Available Now - 20% Off
We may make a commission if you purchase anything via the adverts or links on this page.
Betterhelp is for anyone suffering from mental health issues. Whether you suffer from anxiety, depression, weed addiction, eating disorders, or just need someone to speak to, Betterhelp can pair you with a qualified therapist.
In the wake of the pandemic, an increasing number of people have sought out therapeutic and conseling services to help with weed cessation. Better Help has seen a massive rise in people seeking help over the last two to three years.
If you or someone you care about is smoking or ingesting a level of weed that makes their life become unmanageable, Betterhelp has counselors and therapists on hand to help for less that $90 per week.
Specializations | Burnout, Anxiety, Depression, Stress, Anger Management, Dependencies, Grief, Seasonal Depressive Disorder, Life Crisis, Smoking Cessation, Weed Cessation (among others)
Betterhelp Cost | The standard fee for BetterHelp therapy is only $60 to $90 per week or $240 to $360 per month.
Key Takeaways |
- Largest online therapy platform
- Low cost
- Good for stopping weed
- Messaging
- Live video
- Phone calls
- Live chat
- No lock in contracts
- Cancel anytime
- Licensed and accredited therapists
Discounts Available | We have negotiated a generous 20% discount for readers of our website. Press Here to get 20% Off
